ProCE Banner Activity

My Thoughts on the Clinical Implications of the Expanded Indication for Niraparib

Clinical Thought
Gain expert insights from Kathleen Moore, MD, on key findings from the QUADRA trial that led to FDA label expansion of niraparib in ovarian cancer.

Released: November 26, 2019

Expiration: November 24, 2020

Share

Faculty

Kathleen N. Moore

Kathleen N. Moore, MD, MS, FASCO

Virginia Kerley Cade Chair in Developmental Therapeutics
Deputy Director, Stephenson Cancer Center at OU Health
Oklahoma City, Oklahoma

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

Supported by independent educational grants from

Clovis Oncology

Tesaro

Faculty Disclosure

Primary Author

Kathleen N. Moore, MD, MS, FASCO

Virginia Kerley Cade Chair in Developmental Therapeutics
Deputy Director, Stephenson Cancer Center at OU Health
Oklahoma City, Oklahoma

Kathleen Moore, MD, has disclosed that she has received consulting fees from Aravive, AstraZeneca, Clovis, Cue Biopharma, Genentech/Roche, Merck, OncoMed, Pfizer, Samumed, Tesaro, and VBL Therapeutics.